Please login to the form below

Not currently logged in
Email:
Password:

Wave Life Sciences

This page shows the latest Wave Life Sciences news and features for those working in and with pharma, biotech and healthcare.

Wave’s challenge to Sarepta in Duchenne falls flat

Wave’s challenge to Sarepta in Duchenne falls flat

Shares in the company down more than 50%. Wave Life Sciences has abandoned two drugs for Duchenne muscular dystrophy, including phase 2/3 candidate suvodirsen, in a move that takes the ... The demise of Wave’s programmes leaves Japan’s Nippon

Latest news

  • UniQure gets speedy US review for Huntington’s gene therapy UniQure gets speedy US review for Huntington’s gene therapy

    The biotech’s one-shot gene therapy approach is up against other huntingtin-lowering therapies, including antisense-based therapies from Roche/Ionis and Takeda/Wave Life Sciences that attempt to bind ... Takeda and Wave have phase 1b/2a trial on the go

  • Duchenne UK and pharma partner pilot data-sharing HTA approach Duchenne UK and pharma partner pilot data-sharing HTA approach

    The pharma partners - Roche, Sarepta Therapeutics, Solid Biosciences, Summit and Wave Life Sciences - all have an interest in DMD as well as other rare and orphan diseases that can have difficulties ... With a wave of treatments in, or about to enter

  • Pfizer signs $900m-plus deal with WAVE for metabolic R&D Pfizer signs $900m-plus deal with WAVE for metabolic R&D

    Pfizer has bolstered its metabolic disease R&D with a $911m collaboration with WAVE Life Sciences focusing on nucleic acid-based therapies. ... The deal gives WAVE scope to use GalNAc in certain projects that lie outside the limits of the collaboration.

  • Life sciences sector 'aggressively embracing' new technology Life sciences sector 'aggressively embracing' new technology

    report. The IMS Institute for Healthcare Informatics also found life sciences companies are 'aggressively embracing' new technology-driven approaches. ... The study, Riding the Information Technology Wave in Life Sciences: Priorities, Pitfalls and Promise

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Why everyone in pharma is bending over backwards to be agile Why everyone in pharma is bending over backwards to be agile

    Flexibility is the new key to success. By Philip Atkinson. There is currently a significant wave of transformation across the life sciences sector. ... This takes time, but in all areas of life we need to respond quickly to a stimulus – it hurts when

  • 25 Women Leaders in UK Healthcare 25 Women Leaders in UK Healthcare

    1. MELANIE LEE. Research leader. Melanie Lee is one of the most respected leaders in UK life sciences, having excelled in roles across the spectrum, from her early work in academic ... 8. DR SAM ROBERTS. Innovation translator. The UK life sciences sector

  • Deal Watch May 2016 Deal Watch May 2016

    950+ contingent 50. WaVe Life Sciences/ Pfizer. Licence and collaboration. Nucleic acid therapies for metabolic disorders using stereopure platform; $40m upfront includes $30m equity, option to up to 5 programmes.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....